Viridian Therapeutics, Inc. cash flow to debt ratio of -545.23% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Viridian Therapeutics, Inc.'s free cash flow has decreased 18.92% from $-232.83M last year to $-276.89M, signaling decreasing performance

Viridian Therapeutics, Inc.'s debt to equity ratio is 0.37, which means that the company's assets are healthy financed, signaling financial stability.

Viridian Therapeutics, Inc.'s debt has increased relative to shareholder equity from 0.03 last year to 0.37 today, signaling weakened financials

Viridian Therapeutics, Inc. has a net cash position, so leverage is healthy.

Viridian Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Viridian Therapeutics, Inc.'s profit margin was -89.39K% last year and is -544.06% this year, signaling increasing performance

Viridian Therapeutics, Inc.'s short-term assets of $894.23M exceed its short-term liabilities of $70.70M

Viridian Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Viridian Therapeutics, Inc.'s return on equity of -61.35%, is lower than 15.00%, indicating bad performance

Viridian Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Viridian Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Viridian Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Viridian Therapeutics, Inc. has negative free cash flow, indicating cash burn

Viridian Therapeutics, Inc.'s yearly earnings has decreased 26.91% since last year from $-269.95M to $-342.60M, signaling decreasing performance

Viridian Therapeutics, Inc.'s yearly revenue has increased 23.36K% since last year from $302.00K to $70.85M, signaling increasing performance

ROIC -39.18% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Viridian Therapeutics, Inc.'s 3-year revenue CAGR of 241.95% is positive, indicating growing revenue over the past 3 years

Viridian Therapeutics, Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Viridian Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Viridian Therapeutics, Inc. is overvalued relative to its fair value price of 2.69 based on Base Cash Flow Valuation (DCF) model

Viridian Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Viridian Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on Base EBITDA Valuation model

Viridian Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Viridian Therapeutics, Inc. has insufficient data to evaluate this check.

Viridian Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Viridian Therapeutics, Inc. has a price-to-book ratio of 3.34x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Viridian Therapeutics, Inc. has a price-to-sales ratio of 31.05x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue